ADVFN
Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VSee Health shares surge after securing FedRAMP approval and expanding ICU robotics program

Latest News
November 11 2025 10:42AM

Shares of VSee Health Inc. (NASDAQ:VSEE) jumped 10.7% on Tuesday after the telehealth technology company received FedRAMP Moderate authorization, a key certification that allows it to provide secure telemedicine solutions to U.S. federal agencies. The milestone coincides with the company’s push into robotic-assisted care for intensive care units (ICUs).

The approval gives VSee the green light to pursue federal government contracts, broadening its customer base beyond private healthcare systems. At the same time, the company is integrating real-time remote monitoring and robotic intervention tools, enabling clinicians to assist patients in critical conditions from a distance.

“Telehealth isn’t just convenient anymore; it’s essential for saving lives and bending the healthcare cost curve,” said Dr. Imo Aisiku, Co-CEO of VSee Health. “Our FedRAMP milestone opens doors to massive government contracts. We’re not chasing trends — we’re defining them, delivering measurable ROI for enterprises and better outcomes for patients.”

The company’s platform now supports omni-channel consultations, remote physical assessments, and electronic health record (EHR) integration, catering to hospitals, insurers, and government organizations. VSee recently won new contracts, including a major deal to expand public mental health services in a large U.S. county.

VSee’s expansion strategy comes as the U.S. telehealth market is forecast to reach $52.76 billion by 2025 and grow at a compound annual rate of 23.84% through 2034. Management expects that new partnerships and government deals could generate several million dollars in recurring revenue as early as the second quarter of 2026.

VSee Health stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.

Top Stories